There has been significant increase in the detection of incidental pancreatic lesions due to widespread use of cross-sectional imaging like computed tomography and magnetic resonance imaging supplemented with improvements in imaging resolution. Hence, accurate diagnosis (benign, borderline, or malignant lesion) and adequate follow-up is advised for these incidentally detected pancreatic lesions. In this article, we would review the various pancreatic parenchymal (cystic or solid) and ductal lesions (congenital or pathological), discuss the algorithmic approach in management of incidental pancreatic lesions, and highlight the key imaging features for accurate diagnosis.
Introduction
The term "pancreatic incidentaloma" (PI) refers to those lesions in the pancreas that are diagnosed incidentally when obtaining an imaging study of the abdomen not intended to look for a pancreatic pathological process. 1 This phenomenon is not new to the pancreas and has been quite often observed in other organs such as adrenal glands, thyroid, parathyroid, pituitary, liver, prostate, and kidneys. The first case of PI was described by Kostiuk in 2001. 2 Incidental pancreatic cysts are frequently encountered now due to advancements and easy availability of imaging. The reported incidence of incidental cystic pancreatic lesions varies, depending on the imaging technique used. In computed tomography (CT), the prevalence varies from 0.5 to 3%, whereas in magnetic resonance imaging (MRI), this prevalence increases to 18 to 19.6%. 3, 4 In a postmortem study by Kimura et al, cysts less than 1 cm in size were detected in 24% of cases. 5 Recent published studies have shown that the incidence of incidental PI is rising. 6 When a PI is encountered, the first aim is to classify whether it is a pancreatic parenchymal or ductal lesion. PIs in the pancreatic parenchyma can be either cystic or solid. Incidental lesions in the main pancreatic duct (MPD) can be congenital variations or a pathological process involving the MPD. The second aim is to further classify the lesion into benign or malignant. Various cystic and solid incidentalomas in the pancreatic parenchyma are listed in ►Table 1. 7
Incidental Cystic Pancreatic Tumors
Most incidental cystic pancreatic lesions are benign. 8, 9 The first step is to differentiate these cystic lesions from pancreatic pseudocysts. Serous cystadenoma, mucinous cystic lesions, and intraductal papillary mucinous neoplasms (IPMNs) account for more than 90% of primary cystic pancreatic tumors. 10 Most of the patients are asymptomatic at the time of presentation. Symptomatic patients may present with abdominal pain, jaundice, weight loss, and/or recurrent episodes of pancreatitis. Morphological classification of cystic lesions of the pancreas is given in ►Table 2. 11
Unilocular Cysts
Pancreatic pseudocysts are the most commonly encountered unilocular cysts. Others include mucinous and serous cystadenoma, lymphoepithelial cysts, retention cyst, developmental cyst, epidermoid cyst in intrapancreatic spleen, endometrial cyst, and cystic neuroendocrine tumor or an infectious cyst (►Figs. 1 and 2). A unilocular lesion in Ann Natl Acad Med Sci (India) 2019;55:6-13 a patient with a clinical history of pancreatitis is almost always a pseudocyst. A lobulated unilocular cyst located in the head of the pancreas should raise the suspicion of a serous cystadenoma.
Microcystic Lesions
The most important differential diagnosis of a microcystic lesion in the pancreas is serous cystadenoma. It usually demonstrates a polycystic or microcystic pattern consisting of cysts up to 2 cm in size. They are usually lobulated. The septa and wall may show enhancement (►Fig. 3). A stellate pattern of calcification is visible in 30% of the patients and is considered a characteristic of a serous cystadenoma. 12 A rare Pancreatic Incidentalomas Surekha, Varshney differential diagnosis of a microcystic lesion in the pancreas is a microcystic variant of ductal adenocarcinoma. 13
Macrocystic Lesions
Mucinous cystic neoplasms (cystadenomas) and branchduct (BD) IPMNs usually present as macrocystic lesions. Mucinous cystadenomas mainly involve the body and tail of the pancreas and do not communicate with the MPD. It is important to differentiate serous from mucinous cystic neoplasm as surgery is the treatment of choice in mucinous cystic neoplasm. 14 A peripheral eggshell calcification is highly suggestive of a potentially malignant mucinous cystic neoplasm. 15 Other differential diagnoses of macrocystic lesions in the pancreas are lymphangiomas, lymphoepithelial cysts, infectious cysts, mesothelial cysts, and duplication cysts. 18, 19 Polycystic disease of the pancreas is also known as dysontogenetic cysts or congenital cysts of the pancreas. It is a very rare entity that may occur as a solitary cyst, polycystic disease in association with renal cysts, and liver, central nervous system, or retinal abnormalities. Pancreatic involvement in VHL is in the form of simple cysts (71%), serous cystadenomas (15%), pancreatic neuroendocrine tumors (pNETs; 10%) and rarely cystic replacement of the entire pancreas. 20, 21 Kim et al 22 have shown that pancreatic cysts are five times more prevalent in patients with ADPKD with PKD2 mutation than in patients with PKD1 mutation. PKD1 has a more aggressive disease course, with an earlier age of symptom onset, end-stage renal disease, and death. Thus, the potential to discriminate PKD1 from PKD2 on MRI has important prognostic implications. MRI identification of pancreatic cysts in ADPKD significantly increases the likelihood that a PKD2 mutation is present. 23, 24 
Cyst with Solid Component (Solid Cystic)

Cyst with Ductal Communication
Tumors included in this subgroup are IPMNs, collections postpancreatitis as a part of disconnected duct syndrome, and retention cysts. IPMNs are more common in elderly males in the sixth to seventh decade of life. Three types of IPMNs may be observed: main duct, BD, and mixed variant. 25 Retention cysts are cystic dilatation of the pancreatic duct. It may or may not be associated with an obstructive cause such as calculi, stricture, mucin plugs, and tumors. 26
Multifocal Cystic Lesions
BD-IPMN, pseudocysts, serous cystadenomas, neuroendocrine tumors, developmental cysts, and epithelial cysts can be multifocal and should be considered in the differential diagnoses of multifocal cystic lesions of the pancreas. 11
Incidental Solid Pancreatic Tumors
The incidence of benign disease in solid pancreatic tumors suspicious of cancer ranges from 6 to 21%. Chronic pancreatitis presenting as inflammatory pancreatic mass accounts for almost 70% of the benign lesions, 27 with alcoholic pancreatitis being the most common cause (60%) with autoimmune pancreatitis (AIP) in up to 11% of the patients. 28, 29 Pancreatic Adenocarcinoma
The most frequent solid lesion in the pancreas is pancreatic ductal adenocarcinoma (PDAC). Symptomatic patients present with advanced disease at the time of diagnosis (extensive local disease in ~40% and metastases in 40-55%), leaving less than 20% of patients as candidates for potentially curative resection. 30, 31 The earliest imaging finding of a PDAC before a mass becomes apparent is pancreatic ductal dilatation or pancreatic duct cutoff. On imaging, pancreatic carcinomas (PCs) are hypovascular, hypoenhancing lesions when compared with the surrounding pancreatic parenchyma. On MRI, most PDACs are hypointense on unenhanced T1-weighted sequences when compared with the surrounding pancreas and are hypointense or isointense on T2-weighted images. 32, 33 The sensitivity and specificity of fluoro-2-deoxy-d-glucosepositron emission tomography (FDG-PET) for the diagnosis of PC in patients with normal blood glucose levels range from 85 to 100% and 67 to 99%, respectively. Combination of PET and CT may offer a better accuracy. 34 Serum tumor markers can be helpful in differentiating benign from malignant pancreatic masses. The addition of other tumor markers such as Ca-125 does not increase the diagnostic accuracy of CA19-9 and is the gold standard marker for PDAC with sensitivity and specificity as high as 87 and 98%, respectively. 35
Pancreatic Neuroendocrine Tumors
Over the last decade, the wide use of imaging technology has led to the rising incidence of pNETs. pNETs are rare and account for 2 to 4% of all pancreatic neoplasms, with an incidence of 1.5 in 100,000. 36, 37 In recent years, the detection of incidentally nonfunctioning pNETs (NF-pNETs) has rapidly increased due to the widespread use of endoscopic and cross-sectional imaging. Nearly 60% secrete one or more biologically active peptides, resulting in clinical syndromes. The most frequent functioning tumors are insulinomas, gastrinomas, glucagonomas, VIPomas (a pancreatic neuroendocrine tumor that secretes vasoactive intestinal peptide), and somatostatinomas. Between 30 and 40% of pNETs are Pancreatic Incidentalomas Surekha, Varshney nonfunctioning, and this is more likely to be discovered incidentally when symptoms due to the presence of the mass are not yet obvious. 38 On CT scan, most pNETs are isodense or moderately hypodense masses showing good arterial enhancement (►Fig. 4). Calcification, necrosis, and cystic degeneration seem to be more common in large nonfunctioning tumors or with malignant transformation. MRI has a diagnostic sensitivity of 78 to 91%, which is equivalent to that of dynamic CT. 39, 40 On MRI, pNETs show low signal intensity on T1-weighted images and high signal intensity on T2-weighted images. 41, 42 The most important imaging differential diagnosis is intrapancreatic spleen, which shows enhancement characteristics similar to those of splenic parenchyma (►Fig. 5).
Inflammatory Pancreatic Mass
The combination of acute pancreatitis and cancer is unusual. Pancreatic cancer represents 1 to 2% of acute pancreatitis etiologies, and only 3% of cancers manifest as acute pancreatitis. 43 The risk of developing pancreatic cancer in patients with chronic pancreatitis is around 15 times higher than in the average population. 44 Dilatation of the pancreatic duct, and double-duct sign with both biliary and pancreatic obstruction or interruption of the pancreatic duct are unusual and should lead to considering an underlying carcinoma. Sheathing of the celiac trunk and/or mesenteric artery is seen in 30 to 60% of CT scans of adenocarcinoma. 45 But this can also be seen in AIP or IgG4 (immunoglobulin G4 related) conditions with extrapancreatic lesions in sclerosing mesenteritis and retroperitoneal fibrosis. 46 Adenocarcinoma developing in the background of chronic pancreatitis is difficult to detect on imaging. In the context of chronic pancreatitis, calcifications displaced by the mass is a pointer suggesting a coexisting PC. 47, 48 Nearly 10% of presumed PCs that are surgically operated have been composed of pseudotumoral forms of pancreatitis, nearly half of which are thought to be focal forms of AIP, involving mainly the head. 49, 50 Certain imaging criteria are helpful in diagnosing AIP, such as both early and delayed homogeneous enhancement of the lesion close to that of normal parenchyma, peripheral pseudocapsule, a duct visible in the mass with an hourglass stenosis, absence of upstream atrophy or marked dilatation of the pancreatic duct (<4 mm), multifocal involvement, absence of vascular involvement, and presence of extrapancreatic manifestations. 51
Incidental Congenital Main Pancreatic Duct Anomalies
Congenital anomalies and normal variants of the pancreas and pancreatic duct may not be detected until adulthood and are often discovered as an incidental finding in asymptomatic patients. These anomalies are considered and detected only when patients present with idiopathic pancreatitis. MRCP is the modality of choice nowadays for the assessment of congenital pancreatic anomalies since it depicts ductal anatomy rapidly and noninvasively. Anatomic variations and developmental anomalies of the pancreas and pancreatic duct include variations of the course of the pancreatic duct (descending, sigmoid, vertical, and loop-shaped course), variation of the configuration of the pancreatic duct (bifid configuration with dominant duct of Wirsung [60%], dominant duct of Santorini without divisum [1%], absent duct of Santorini, and ansa pancreatica), duplication anomalies, anomalous pancreaticobiliary ductal junction, pancreas divisum (4-14%), annular pancreas, ectopic pancreas, and pancreatic agenesis and hypoplasia of the dorsal pancreas and accessory pancreatic lobe. 52, 53 Incidental Pathological Processes Involving the MPD Genetic mutation associated pancreatitis (GMAP) also sometimes referred to as idiopathic painless chronic pancreatitis can present as an incidental ductal disease process while imaging for symptoms not related to the pancreas. Several gene mutations associated with chronic pancreatitis have been identified, with the most frequent involving the CFTR (cystic fibrosis transmembrane regulator) gene, the SPINK1 (serine protease inhibitor, Kazal type 1) gene, and the PRSS1 (cationic trypsinogen) gene. According to some authors, the patients with pancreatitis associated with one of these gene mutations show onset at a younger age than those with pancreatitis related to other factors, even though the diagnosis is often late compared with the appearance of symptoms. Accurate diagnosis of GMAP is important for a careful follow-up of these patients, as the risk of developing pancreatic adenocarcinoma is higher in this group than in the normal population or in patients affected by chronic pancreatitis not associated with gene mutations. On imaging, typical bull's eye pattern of stones, with a dense peripheral rim and a noncalcified radiolucent central core with stones greater than 15 mm in size, is seen. 54, 55 pNETs expressing serotonin (carcinoid tumors) account for a small portion of neuroendocrine tumors. 56 Segmental changes in the pancreatic duct are being increasingly encountered as patients undergo abdominal imaging for Table 3 Practical tips in pancreatic incidentalomas CT using pancreatic protocol is the imaging of choice for solid lesions MRI is the modality of choice in characterizing and for follow-up of cystic lesions EUS and fluid aspirate analysis are used for indeterminate lesions Solid pancreatic incidentalomas are considered malignant unless until proven otherwise High amylase and CEA levels in fluid suggest pseudocyst and mucinous neoplasms, respectively Simple cysts up to 3 cm in size with no worrisome features can be safely monitored Surgery is considered for MCN, SPN, MD-IPMN, mixed IPMN Surgery is considered for cysts > 3 cm and serous cystadenoma > 4 cm Solid lesions up to 2 cm in size are likely to be malignant and will require surgical intervention Small pNETs (<1 cm) are simply monitored Larger pNETs (>2 cm) lesions are treated by enucleation or resection Generally, pancreatic incidentalomas have a better prognosis than symptomatic lesions Abbreviations: CEA, carcinoembyronic antigen; CT, computed tomography; EUS, endoscopic ultrasound; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystadenoma; MD-IPMN, main-duct intraductal papillary mucinous neoplasm; MRI, magnetic resonance imaging; pNETs, pancreatic neuroendocrine tumors; SPN, solid pseudopapillary tumor. evaluation of a variety of symptoms. The two most common causes of segmental pancreatic duct dilatation and pancreatic atrophy are chronic pancreatitis and malignant neoplasms such as PDAC. In rare instances, small serotonin secretin neuroendocrine tumors (serotoninoma) can induce fibrogenesis due to production of 5-hydroxyindoleacetic acid and serotonin, leading to obstruction of the pancreatic duct. 57, 58 These tumors are often detected incidentally while imaging patients for symptoms other than pancreatic etiology.
Management of Incidental Pancreatic Lesions
Most guidelines reach the consensus that the presence of a potentially resectable solid pancreatic mass in a CT scan or endoscopic ultrasound (US) in an otherwise healthy patient, with no clinical or biochemical characteristics suggesting a benign condition, should prompt surgical treatment. 27 Management of incidentally detected pNETs is a debatable topic. Indications for surgery in pNETs are functioning pNET and Pancreatic Incidentalomas Surekha, Varshney NF-pNETs > 2 cm. pNET < 1 cm can be kept on monitoring, and pNETs of 1 to 2 cm should be considered for enucleation if superficial in location. [59] [60] [61] Various published guidelines for the management of cystic lesions recommend resection of potentially malignant tumors such as mucinous cystadenomas, solid pseudopapillary tumors, and main and mixed type of intraductal papillary mucinous neoplasms and observe benign lesions such as serous cystadenoma (< 4 cm) and BD IPMN. [62] [63] [64] [65] Close follow-up and surgical consideration are recommended in cases with worrisome features (symptomatic, cytology suspicious for malignancy, enhancing mural nodule < 5 mm, MPD > 6 mm, cyst size increasing > 2 mm/year, elevated CA19-9). [62] [63] [64] [65] The International Association of Pancreatology recommends surveillance for simple cysts < 3 cm in size. Patients with cysts < 1 cm are imaged at an interval of 2 to 3 years (CT/MRI), those with cysts 1 to 2 cm in diameter at an interval of 1 year (CT/MRI), and those with cysts of size 2 to 3 cm at an interval of 3 to 6 months (preferably endoscopic US). 64 An algorithmic approach to the management of PIs is illustrated in ►Fig. 6.
Conclusion
PIs are increasingly encountered by the radiologists today and are worrisome. These can be cystic or solid. An incidentally discovered pancreatic cystic lesion without any evidence of worrisome features and of < 2 cm is highly unlikely to cause morbidity or mortality. Around half of these lesions may eventually grow to be larger than 2 cm; therefore, adequate follow-up is advised. Solid PIs > 1 cm are potentially considered malignant, unless proven otherwise, and resection or enucleation is recommended. Key practical tips for the radiologists when dealing with PIs are given in ►Table 3.
